Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nateglinide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Nateglinide. Displaying page 1 of 1.
    EudraCT Number: 2006-006384-24 Sponsor Protocol Number: M1E-JR-004 Start Date*: 2007-05-29
    Sponsor Name:Johan Wolfgang Goethe Universität - Department of Internal medicine I, Division Endocrinology
    Full Title: Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“
    Medical condition: Non-insulin demanding type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004748-30 Sponsor Protocol Number: GLP-1(7-36) Start Date*: 2006-08-14
    Sponsor Name:Royal Victoria Hospital Belfast
    Full Title: Therapeutic implications of the effects of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001873-42 Sponsor Protocol Number: D1690R00009 Start Date*: 2015-10-27
    Sponsor Name:University of Liverpool
    Full Title: Pragmatic Randomised 104 Week Multicentre Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013157-15 Sponsor Protocol Number: 1218.74 Start Date*: 2010-10-14
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...
    Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002462-35 Sponsor Protocol Number: NN5401-1792 Start Date*: 2007-12-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metf...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002476-33 Sponsor Protocol Number: NN5401-1791 Start Date*: 2007-11-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: Ensayo clínico abierto y aleatorizado con tres grupos paralelos  con ajuste de dosis y 16 semanas de tratamiento para comparar la administración una vez al día de insulina SIAC 30(B), SIAC 45(B) e ...
    Medical condition: Diabetes Mellitus Tipo 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001258-94 Sponsor Protocol Number: A2171018 Start Date*: 2005-12-23
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera®) on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Po...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10012601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004864-29 Sponsor Protocol Number: F3Z-EW-IOPJ Start Date*: 2008-02-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 15:27:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA